Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Nov 3, 2026Score 11/3056% above fair value
$30.67+0.15 (+0.49%)
Close on Nov 2, 2026Market cap $174.81BP/E 40.4Yield 5.61%
Pfizer Talzenna (talazoparib by Year
Talzenna (talazoparib — PARP inhibitor) — U.S. reported YoY (%) (%)
Pfizer Talzenna (talazoparib: 51.0% in FY2025.
Latest, FY2025
51.0%
Period ended Dec 31, 2025
Change on a year earlier
–
History
1 years
Since FY2025
Sources
1
Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03)
Where the FY2025 figure comes from
“|| Talzenna | 182 | 117 | 55% | 54% | 133 | 88 | 51% | 50 | 30 | 67% | 63%”
Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Reported in Form 8-K Revenue Tables.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Talzenna (talazoparib — PARP inhibitor) — U.S. reported YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 51.0% | – | Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗ |
Cite this data
StockData. (2026). Pfizer Talzenna (talazoparib (%), annual FY2025–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/talzenna-yoy-us
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.